The stock of Puma Biotechnology Inc (PBYI) closed the regular trading session at $2.33, gaining 4.95% from the previous trading session. On the last check, PBYI stock remained bullish, gaining 8.58% to $2.53, in the pre-market. The firm published the fiscal performance for Q4 and FY21. PBYI also filed the form 10-K and 8-K with the SEC on 3 March 2022.
PBYI key financials
On 3 March 2022, Puma (PBYI) published its financial performance for Q4 and FY2021, which concluded on 31 December 2021. The main highlights of fiscal performance are
- PBYI had the total sales of $55.4 million in Q4 of FY21 versus $52.6 million in Q4 of FY20. This marks a growth of 5.3%. Also, the sales in 2021 expanded by 12.4% to $253.2 million against $225.1 million in 2020. Further, the total sales beat the estimates by 16.14%.
- The firm had an operative income of $6.8 million versus the operative loss of $11.3 million in the same period last year. Also, PBYI had an operative income of $1.3 million in 2021 against the operative loss of $30.4 million in 2020.
- The company had a total income of $4.2 million in Q4 of FY21 versus the total loss of $15 million in the same period of last year. Also, the total loss for 2021 was $29.1 million in comparison to $60 million in 2020, reducing by 51.5%.
- Moreover, the EPS of $0.10 in Q4 of FY21 versus the loss of $0.38 per share. Also, the loss of $0.72 per stock in 2021. The EPS in Q4 of FY21 exceeded the estimate of a loss of $0.11 per stock.
CEO Remarks:
The CEO of PBYI stated that during the final quarter of 2021 Puma accomplished its crucial achievements. They incorporated the introduction of information from the preliminary summit at the 2021 San Antonio Breast Cancer Symposium. He further added that they were satisfied to declare the augmentation of 5 extra years to the U.S. patent term of NERLYNX in the quarter too.
Mr. Auerbach concluded that they stay focused on furnishing neratinib to the victims with HER2 positive breast malignant growth.
